Future drug treatments for type 2 diabetes

Clifford J. Bailey*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish
Title of host publicationTextbook of diabetes
EditorsRichard I.G. Holt, Clive S. Cockram, Allan Flyvbjerg, Barry J. Goldstein
PublisherWiley-Blackwell
Pages1017-1044
Number of pages28
Edition4th
ISBN (Electronic)978-1-4443-2480-8
ISBN (Print)978-1-4051-9181-4
DOIs
Publication statusPublished - 9 Jul 2010

Keywords

  • classification of new antidiabetic agents
  • development of new antidiabetic agents
  • endothelial nitric oxide synthase (eNOS)
  • inhibitors of intestinal carbohydrate digestion and absorption
  • insulin receptor and early post-receptor potentiation
  • insulin receptor substrate 1 (IRS1)
  • other insulin receptor potentiators
  • peroxisome proliferator-activated receptor γ agonists
  • potentiators of insulin secretion
  • sulfonylurea receptor 1
  • SUR1

Research Output

Oral antidiabetic agents

Bailey, C. J. & Krentz, A. J., 9 Jul 2010, Textbook of diabetes. Holt, R. I. G., Cockram, C. S., Flyvbjerg, A. & Goldstein, B. J. (eds.). 4th ed. Wiley-Blackwell, p. 452-477 26 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Cite this

Bailey, C. J. (2010). Future drug treatments for type 2 diabetes. In R. I. G. Holt, C. S. Cockram, A. Flyvbjerg, & B. J. Goldstein (Eds.), Textbook of diabetes (4th ed., pp. 1017-1044). Wiley-Blackwell. https://doi.org/10.1002/9781444324808.ch60